Programmed Cell Death in Pathogenic Fungi

Mark Ramsdale

School of Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, United Kingdom

Tel: +44(0)1392-269173
Fax: +44(0)1392-263700
E-mail: M.Ramsdale@exeter.ac.uk

Keywords: Antifungal drugs; Candida albicans; Apoptosis; Necrosis

Abstract

Greater understanding of programmed cell death (PCD) responses in pathogenic fungi may offer a chance of exploiting the fungal molecular death machinery to control fungal infections. Clearly identifiable differences between the death machineries of pathogens and their hosts, makes this a feasible target. Evidence for PCD in a range of pathogenic fungi is discussed alongside an evaluation of the capacity of existing antifungal agents to promote apoptosis and other forms of cell death. Information about death related signalling pathways that have been examined in pathogens as diverse as Candida albicans, Aspergillus fumigatus, Magnaporthe grisea and Colletotrichum trifolii are discussed.

1. Introduction

Programmed cell death appears to be a ubiquitous feature of living systems, and has been described in one form or another in the majority of phylogenetic lineages including eubacteria, protists, plants and animals [1-8]. The wide spread occurrence of PCD hints either at an ancient origin, or suggests that it is an aspect of the life of both unicellular and multicellular organisms which has evolved many times over. In either case, PCD plays an important part in the life-histories of most organisms including fungi [9,10]. Differences in the nature of death responses are often a reflection of basic differences in the cell biology of the organisms under consideration. It is now apparent however that at a deep-rooted level, related molecules are taking part in the cell death decisions of organisms as diverse as bacteria, yeast, plants, worms, flies and man. Much research has focused on this similarity, but when differences are found they should be celebrated, as they may, in the case of pathogenic organisms provide a new avenue of investigation that could be exploited in the design of drugs that fight infectious diseases of plants and animals.

The core features of the PCD responses in mammals are defined by a set of morphological and biochemical changes that are mediated by external (extrinsic) or internal (intrinsic) cell suicide programs. In the intrinsic death pathway, death signals induce the release of mitochondrial proteins, [11-13] resulting in an amplification of a caspase cascade,[11,14,15]. In the extrinsic pathway, signals mediated by death receptors of the TNF receptor superfamily activate the caspase cascade directly. Caspase independent
suicide pathways may also be initiated in response to stress (eg after exposure of cells to ROS) that involve the translocation of an apoptosis inducing factor (AIF) from the mitochondrion to the nucleus.

PCD is commonly associated with the fragmentation of nuclei and degradation of DNA which can be linked to the activity of a number of different nucleases [16-23]. PCD is also accompanied by a loss of phospholipid asymmetry that involves the translocation of phophatidylserine (PS) to the outer leaflet of the plasma membrane [24,25]. Such lipid bilayer rearrangements require the activation of non-specific bidirectional phospholipid flippases and floppases along with the inhibition of aminophospholipid translocases, or scramblases that normally recycle PS to the inner leaflet [26,27]. ATP-binding cassette transporters such as ABCA-1 and CED-7 have been implicated in transbilayer redistribution of PS [28]; perhaps of some significance therefore is the finding that homologues of such ABC-transporter enzymes in fungi have been implicated in antifungal drug resistance [29-31] though their roles in fungal cell death per se have yet to be explored.

2. Understanding fungal PCD has wide implications

Programmed cell death responses have now been described in a range of fungi [9,10] though the majority of studies are focused on the yeasts Saccharomyces cerevisiae, Schizosaccharomyces pombe and Candida albicans [32-37]. Fungal cells dying under a range of conditions exhibit several markers characteristic of apoptosis, including the rapid exposure of PS at the outer cell membrane (revealed by annexin binding), the margination of chromatin in nuclei, nuclear fragmentation and the degradation of DNA (revealed by the TUNEL test). In many cases it has been shown that exposure of cells to cycloheximide prevents these death associated changes, indicating that the death response requires active protein synthesis (eg [38]).

Functional analyses of genes in yeast have revealed that there are some similarities at the molecular level between fungal apoptosis and apoptosis of higher eukaryotes, with the identification of homologues of caspase-like cysteine proteases [39], AIF [40] and Htr2A/Omi [41]. On the whole it is anticipated that the proteins responsible for fungal cell death will be sufficiently distinct from their mammalian counterparts to make drug therapies feasible since bioinformatic screens of fungal genomes have shown that many of the known components of higher organism apoptosis are missing or highly divergent at the amino acid level [42]. The discovery of PCD responses in the model pathogenic fungi C. albicans [36,37], Aspergillus fumigatus [43,44] and Magnaporthe grisea [45] raises the long-term possibility of developing novel antifungal drugs and fungicides that clear infections by activating fungal cell suicide. Identification of the endogenous molecular switches that trigger fungal apoptosis is of paramount importance if we are to achieve these aims.

3. Fungal pathogens of man, animals and plants
Fungi can affect human welfare by destroying crop plants [46] or by causing life-threatening diseases in immunocompromised individuals [47] - see Table 1 for a summary of the pathogenic fungal species considered in this review and the literature considered.

In humans the major threats to our health are posed by pleomorphic fungi, ie those that can grow in yeast, pseudohyphal or filamentous growth forms. Most notable amongst the pleomorphic fungal pathogens is *Candida albicans* and its close relatives (*C. dubliniensis*, *C. krusei*, *C. parapsilosis*, *C. tropicalis*), as well as the more distant relative, *Candida glabrata*. The other major human pathogenic fungi that cause life-threatening disease are *Aspergillus fumigatus*, *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, *Paracoccidioides brasiliensis* and *Blastomyces dermatidis*. A number of additional human pathogens are now also emerging as significant threats to specific patient groups (particularly HIV-positive patients) including *Penicillium marneffei* [48] and *Pneumocystis jiroveci*, formerly known as *P. carinii* [49]. In addition to these pathogens, a large number of clinically important dermatophyte fungi (numbering in excess of 600) can cause both irritating and/or disfiguring superficial infections. Amongst these, *Malassezia globosa*, a yeast that causes dandruff, as well as more severe seborrhic dermatitis, affects more than 50% of the human population and may contribute to atopic eczema in sensitized patients [50,51]. *Trichophyton rubrum* and *T. mentagrophytes*, cause superficial skin infections most notably athletes foot, and are considered to be the second most common cause of skin infections after acne [52].

*Candida albicans* has become a molecular genetics work-horse for the study of pathogenicity, virulence and fungal development [53]. *Candida* species are typically commensal organisms, present on about 50% of the population at any one time [54]. Over a lifetime however, some 80% of women suffer from clinical *Candida* infections, and about 5% of these thrush infections can be recurrent, with some infections becoming resistant to antifungal therapy. In immuno-compromised individuals, *C. albicans* can produce mild but irritating, superficial infections of the oral and vaginal mucosa. In severely immuno-compromised patients, *C. albicans* can produce a disseminated systemic infection which if not treated effectively is associated with a high incidence of mortality. Systemic *C. albicans* infections typically occur in patients undergoing chemotherapy or organ transplantation and, depending upon the patient group, one-third to one-half of these infections are fatal. The incidence of infection amongst premature and small babies can be as high as 7%, and over half of these patients may not survive [55]. *C. albicans* is also the fourth most common hospital acquired infection and typically extends a patient's stay in hospital by an average of 30 d. The number of clinical *C. albicans* infections in UK hospitals has risen significantly in recent years [56], and the incidence of resistance to traditional antifungal therapies is high [57]. *Candida* infections are therefore both socially and economically devastating.

4. **Major plant pathogenic fungi**

Human pathogenic fungi that cause life-threatening disease represent a small fraction of the species that cause disease. Indeed, whilst the majority of fungi are benign, a large number produce diseases in plants...
affecting crop yields and profit margins which can have serious consequences on both local and global scales.

Arable food production worldwide is mainly based upon four staple crops - rice, wheat, maize and potato [58]. All of these are subject to infection by a significant number of plant pathogenic fungi. Fungicides are vital for the control of plant diseases, which are estimated to cause yield reductions of almost 20% in the major food and cash crops worldwide [59].

Arguably at the top of the list of plant pathogenic fungi is the filamentous ascomycete *Magnaporthe grisea* (sexual state *Pyricularia oryzae*), the causative agent of Rice Blast Disease [46]. Annually, rice blast is responsible for a loss of between 10 and 30% of the rice harvest. Other plant pathogens that pose serious environmental and socioeconomic threats include *Tilletia indica* (Karnal bunt, [60]) and *Puccinia kuehnii* (Sugar Cane Orange Rust [61]). *Cryptonectria parasitica* a basidiomycete pathogen causing Chestnut blight [62,63] and *Ophiostoma* spp another ascomycete (Dutch Elm disease [64]) have also caused major losses in forestry in recent years.

Overall fungi represent 30% of emergent infectious diseases (second only to viral infectious diseases at 47% [65]). Despite extensive breeding programmes for resistance to fungal pathogens, the sheer numbers of fungal propagules in the environment and the ability of fungi to generate diversity through sexual and parasyexual recombination often mean that control is limited to only a few seasons before new virulent strains arise.

Amongst the oomycetes, *Phytophthora infestans* (Potato late blight) is still the most important threat to potato production worldwide [66]. This pathogen which coevolved with wild potato (*Solanum*) species, was transported to Mexico from South America [67] from where it spread to cultivated crops worldwide. It was introduced into the USA in about 1840 and was subsequently transported to Europe where it decimated potato production, causing the Irish potato famine and the forced migration of five million people [68]. Blight was re-introduced from Mexico into the USA and Canada during the early 1990s [69,70] and outbreaks of blight continue to this day, causing devastating local and global epidemics potentiated by the emergence of virulent fungicide-resistant strains such as US-8 [71]. Other species of *Phytophthora* are the cause of major economic and environmental losses including *P. ramorum* in Europe (Sudden Oak death Syndrome [72] and *P. cinnamomi* in Australia (Jarrah Die-back [73]).

### 5. Fungi as pests / spoilage organisms

Fungi also affect our quality of life more indirectly by damaging / spoiling food-stuffs (which leads to both economic losses or the production of food-stuffs contaminated with health-threatening mycotoxins). Fungi can colonize our homes, workplaces and hospitals (damaging property) and following the production of copious quantities of airborne spora, induce allergic reactions that can in some cases be life-threatening eg *Stachybotrys chartarum* [74] and *Aspergillus fumigatus* [75]. Reducing the economic and environmental threats posed by such contamination requires the treatment of foods or property with a range
of preservative agents that can become less effective with prolonged use, and themselves may be considered harmful to our health or the environment.

6. Worldwide economic losses attributed to fungal disease
In 2006 the annual fungicide market aimed at arable crops was estimated to be $7.2 billion [173]). Such massive expenditure is however offset by the economic gains arising from the increase in yields / productivity which are thought to have netted the farming industry $12 billion dollars in additional revenue. At a local level the impact of losing a crop can however be devastating, even when the industry as a whole performs well. Currently the antifungal drug market is of comparable size, estimated to be about $11.9 billion in 2007 [174].

7. Current practice - antifungals and fungicides
The design and implementation of effective antifungal / fungicide therapies is complicated by basic similarities in the cellular organization of pathogenic fungi and their hosts. In a medical setting many antifungal drugs are quite toxic to patients; precluding their long-term use.

Current antifungal treatments used in healthcare largely target essential processes at the fungal cell surface, such as plasma membrane or cell wall biogenesis. Several distinct classes of antifungal drug are currently available for the treatment of clinical fungal infections. Novel antifungals are always under development, but the mainstays of treatment and the most widely used are azoles, polyenes, allylamines, 5-fluorocytosine (5FC) and the echinocandins [76].

The polyene antifungal amphotericin B (AmB) has been used clinically for over 30 years [77]. Formulating AmB with liposomes [78], and lipid complexes [79] has allowed the use of higher doses of AmB, which can be useful in the treatment of recalcitrant infections. The primary mode of action of AmB, in common with other polyene antifungals is thought to arise from its affinity for ergosterol. Integration of AmB into the cell membrane results in the formation of aqueous pores, which lead to altered plasma membrane permeability which is subsequently accompanied by loss of mono- and divalent cations leading to cell death [80]. The minimal inhibitory concentrations (MIC90) of AmB for a variety of species of Candida range from 0.25-1 µg/ml [81], whilst the minimal fungicidal concentrations (MFC) may be up to 2 fold higher. The fungicidal action of AmB makes it useful in the treatment of systemic candidiasis, Candida meningitis and ophthalmitis [76] as well as infections that are traditionally regarded as resistant to azoles eg C. krusei and C. glabrata. Polyenes also have a strong affinity for host sterols, especially cholesterol [82], which is associated with a number of side-effects, most importantly renal toxicity precluding their use in long-term therapy [83]. Resistance to AmB can be intrinsic, with isolates of Candida luscitaniae commonly failing to respond [76]. Acquired resistance, though rare, has been described, and is linked to the selection of mutants that accumulate 3β-ergosta-7,22-dienol and 3β-ergosta-8-dienol, which is associated with a defect in sterol Δ5,6 desaturases [84,85]. Increased catalase activity
has also been found to offset the oxidative (ROS) damage that accompanies AmB treatment of fungal cells which is thought to contribute to its fungicidal properties [86].

Azoles were discovered in the 1960s and have been the mainstay of antifungal therapies for a number of years. Two classes of azole antifungal drug have been developed, N-1 substituted imidazoles (e.g. ketoconazole, clotrimazole) and triazoles (e.g. fluconazole, itraconazole). Azoles target the CYP51A1 cytochrome P450 required for the 14α-demethylation of lanosterol [87] and the Δ22-desaturase involved with the desaturation of ergosta-5,7-dienol [88]. Nitrogen in the imidazole or triazole rings bind to the haem iron of cytochrome P450, inhibiting its action. The interaction depends on the precise conformation of the enzyme, thereby affecting the range of species against which individual azoles are effective. Despite this, azoles do generally possess broad spectrum antifungal properties and are used in the treatment of Candida spp., Cryptococcal infections, H. capsulatum, Coccidioides immitis and dermatophytes. The incidence of resistance to front-line azole antifungals is however one of the major driving forces behind the need to develop new active agents.

Exposure of fungi to 5-Fluorocytosine (5FC) leads to its uptake by cytosine permeases. Once inside a cell, 5FC is deaminated to 5FU and then converted to a nucleoside triphosphate, which when incorporated into RNA causes miscoding. 5FU, itself is also converted to a deoxynucleoside, which can subsequently inhibit thymidylate synthase. 5FC is fungicidal, however its spectrum of activity is limited because of widespread resistance, which is greatest amongst Aspergillus and Candida species [89]. 5-FC is often used in combination therapy with AmB because of the rapid acquisition of resistance by treated infections. Combined therapies often show contradictory responses in vitro, but in vivo animal models of both candidiasis and cryptococcosis do generally respond well [90].

Allylamines were initially developed in the 1970's and include terbinafine, naftidine and structurally related compounds such as tolnaftate. The allylamines inhibit squalene epoxidase, the first enzyme in the committed stage of ergosterol biosynthesis. Allylamines function as reversible, non-competitive inhibitors of squalene epoxidase which leads to ergosterol depletion.

Terbinafine is fungicidal against filamentous dermatophytes, but is only fungistatic against Candida species. Co-treatment of cells with calcineurin inhibitors eg cyclosporin A or FK506 can alter this balance promoting cell death, potentially expanding the utility of this drug [91].

Echinocandins, a class of cyclic lipohexapeptides are the most recent additions to the arsenal of antifungal drugs. Echinocandins have been shown to act as non-competitive inhibitors of β-1,3 glucan synthase which is required for the synthesis of glucan polymers, a major component of the fungal cell wall. Caspofungin, the first commercially available form of echinocandin, displays fungicidal activity against Candida, Aspergillus, Histoplasma, Coccidioides and Blastomyces, however it lacks activity against Cryptococcus and many filamentous fungal pathogens. Micafungin is fungicidal against yeasts [92], but only shows fungistatic properties against aspergilli. Currently there are no reports of resistance developing against these drugs in a clinical setting.
Fungicides used in the treatment of plant disease are very diverse, targeted at both narrow and wide spectra of fungal pathogens. Sulphur containing compounds and strobilurins inhibit the electron transport chain, the latter blocking ubiquinol-cytochrome c oxidoreductase of the cytochrome bc1 complex III [93]. Copper fungicides, dithiocarbamates, substituted aromatics and organophosphorous compounds inhibit the activities of a wide range of enzymes and are relatively non-selective. Benzimidazoles and phenylamides inhibit DNA and RNA synthesis respectively, whilst dicarboximides inhibit both. Cyclopropane carboxamide carprofuramid and phenoxyamide (AC382042) both target scytalone dehydratase and therefore inhibit the synthesis of melanin [94,95]. Azole antifungals are also commonly used in agriculture - potentially with the risk of the development of resistance to such agents amongst clinical isolates.

8. Resistance to antifungals

Resistance of pathogenic fungi to traditional antifungal therapies is a perennial problem and in some clinical situations is alarmingly high [57] making the identification of novel targets for antifungal therapy of some urgency. Resistance to antifungal drugs has both clinical and microbiological components [76]. Successful therapy depends upon a number of factors that not only depend upon the activity of the antifungal therapy but also the pharmacokinetics of the drug in a patient, and the status of their immune system. Resistance can arise through inefficient / inappropriate dosing of patients, inappropriate selection of antifungals, or repeated exposure. In recent years there has been a significant shift towards the isolation of more resistant Candida species in hospitals such as C. glabrata. The administration of azole antifungals as a prophylactic treatment may be a significant contributor to this trend [96,97].

Ideally microbiological resistance will be predictive of clinical resistance, though this is often not the case. Some fungi are intrinsically resistant to specific classes of antifungal drug eg, fluconazole is highly efficacious against C. albicans and C. parapsilosis, but C. glabrata and C. krusei are less susceptible [76].

Low mammalian toxicity and environmental impact as well as low residues in food, and compatibility with integrated pest management programmes are very important features that are required of new antifungals. A balance between cost, potency and safety is a major goal for both the agrochemical and pharmaceutical industries developing new antifungal agents.

9. Examples of PCD induced in pathogenic fungi by antifungal agents

Liao et al. [98] examined physiological changes in C. albicans cells treated with AmB and described three patterns of death. Death was always accompanied by a drop in ATP level but could be subdivided on the basis of plasma membrane integrity and mitochondrial membrane potential. Later, Phillips et al. [36] found that AmB treated cells that were able to exclude propidium iodide and produced ROS corresponded to an apoptotic sub-population. Normal treatment of systemic candidiasis may therefore already reduce infection loads by initiating apoptosis.

Protoplasts of A. fumigatus treated with 0.25-1 µg ml^{-1} AmB stain positive with annexin V, indicating PS translocation to the outer surface of the plasma membrane and also display dsDNA breakage, detectable
with the TUNEL assay [99]. Propidium iodide staining (indicative of necrosis) is less than 20% at 0.25 and 0.5 μg ml⁻¹ AmB, but increases to 85% at higher doses. Pre-incubation of cells with cycloheximide prevents the appearance of apoptotic markers, indicating that killing requires active translation. In contrast, cycloheximide is not able to prevent the formation of propidium iodide positive cells at 1 μg ml⁻¹. Taken together this suggests that at low fungicidal doses, AmB is pro-apoptotic and at higher doses it is pro-necrotic.

Pradimicin A, a broad spectrum fungicidal antifungal agent which binds to mannan residues in the cell wall [100], also induces apoptosis-like cell death in *S. cerevisiae* [101]. Nuclear fragmentation and DNA damage have been observed in yeast cells treated with Pradimicin A, accompanied by an accumulation of reactive oxygen species (ROS). Pradimicin-induced cell death and the accumulation of ROS are prevented by free radical scavengers, suggesting some dependency between the two.

Translational inhibitors such as the phenanthrolines have been shown to kill both mammalian and *C. albicans* cells [102]. Mammalian cells exposed to phenanthrolines show hallmarks of apoptosis, whilst *C. albicans* cells accumulate ROS and display elevated oxygen consumption rates. Nuclear disruption, including enlargement and formation of crescent shaped bodies, has been observed after treatment of yeast cells with some (though not all) silver, copper and manganese metal 'phen' complexes. The production of ROS in the absence of DNA damage could imply that ROS play a primary role as a signal of apoptosis and do not act directly as the DNA damaging agents. Killing by these translational inhibitors may involve a reduction in the levels of cytochrome *b* and *c* and the associated uncoupling of respiratory function which might contribute to the formation of pro-apoptotic ROS. McCann et al. [103] found that phenanthrolines lowered the ratios of reduced/oxidised glutathione, consistent with a pro-oxidant role for the effects of these drugs.

A number of natural antifungal proteins have been found to exert their killing effect by induction of apoptosis like cell death. Osmotin, a member of the PR-5 family of plant defence proteins isolated from tobacco [104]; the basic, cysteine-rich antifungal protein PAF from *Penicillium chrysogenum* [105]; Dermaseptins from amphibian skins [106, 107] and virally encoded yeast killer toxins [108] all appear to induce apoptosis in fungi. RsAFP2 an antifungal peptide isolated from *Raphanus sativus* interacts with glucosyleramides in membranes of fungi resulting in the production of ROS and the death of *C. albicans* cells [109]. Salivary histatins, short histidine rich peptides have also been shown to display both fungistatic and fungicidal activity against a range of *Candida* species [110]. Wunder et al. [110] concluded that histatins did not induce apoptosis in *C. albicans* since they could not find any evidence of DNA laddering or the release of cytochrome *c* when isolated mitochondria were treated with histatin 5. Although elevated levels of ROS were detected following the exposure of cells to histatin 5 or the intracellular expression of an Hst 5 construct, the reduction in viability of *SOD1/2* mutants of *S. cerevisiae* or *SOD1* mutants of *C. albicans* was the same as wild type strains leading the authors to conclude that ROS production merely accompanied the death response, rather than contributing significantly to its fungicidal activity. The significant delay in killing that occurs after treatment has begun does still suggest that histatins might induce some form of
Indeed, whilst the results of Wunder et al. [110] indicate that the primary mode of action of histatins is not the release of cytochrome c from mitochondria, the failure to detect PCD might be due to the fact that canonical markers of apoptosis were not examined in intact cells.

Some antifungal drugs in some species do however appear to operate quite independently of apoptotic mechanisms. For example treatment of protoplasts of \textit{A. fumigatus} with itraconazole or \textit{A. nidulans} with aureobasidin A, AmB or itraconazole does not induce apoptosis [99, 112]. Furthermore, fluconazole toxicity has been shown to be independent of known apoptotic mechanisms in yeast, though this was only tested in the context of a failure of heterologously expressed Bcl-2 to inhibit killing and death characteristics \textit{per se} were not addressed [113].

Finally, radio-labelled monoclonal antibodies have been used to treat \textit{C. neoformans} and \textit{H. capsulatum} infections [114]. An examination of the susceptibility of these species to $^{213}\text{Bi}$ and $^{188}\text{Rd}$ indicated that whilst both species were quite resistant, doses over 4 kGy produced apoptotic changes and killing.

\textbf{10. Studies of PCD in pathogenic fungi}

Direct studies of apoptosis-like cell death in pathogenic fungi have given us some insights that are not possible when looking at model fungi such as \textit{Saccharomyces cerevisiae} in isolation. For example isolates of \textit{Colletotrichum gloeosporioides}, a pathogen of the weed \textit{Aeschynomene virginica}, display enhanced longevity when expressing the anti-apoptotic Bcl-2 protein [115]. Cells are also protected from Bax-induced cell death, and exhibit enhanced stress resistance - all generally consistent with similar experiments in yeast [116]. However the isolates also show enhanced mycelium production and conidiation, and are hypervirulent to host plants. The endogenous apoptosis-related cell machinery may therefore be important for regulating morphogenetic switches, which are critical for proper responses and adaptation of fungal pathogens to different environments [10].

\textit{C. albicans} activates a PCD response (with features reminiscent of apoptosis and necrosis) in response to a variety of environmental stimuli such as acetic acid, hydrogen peroxide as well as AmB [36]. This fungal PCD response is characterised by the rapid appearance of several classical apoptotic markers observed in mammalian cells including a loss of cell viability accompanied by the exclusion of the vital dye propidium iodide; sustained oxygen consumption and metabolic activity during cell death; the production of ROS in apoptotic cells (indicated by oxidation of dihydrorhodamine); the condensation of chromatin at the nuclear margin (visible with DAPI staining and TEM) and the accumulation of DNA breaks (as revealed by TUNEL positive staining). The exposure of PS on the outer surface of the plasma-membrane (as revealed by annexin-FITC labelling) has also been observed. In late stages of cell death, cells lose their ability to exclude propidium iodide linked with the onset of secondary necrosis. Currently, we know very little about the effector molecules that are associated with the onset of PCD in pathogenic fungi. Using the power of functional genetics in fungi it has been possible to ascertain the extent to which individual signalling pathways are necessary, or sufficient for PCD - taking us a step closer to the possible development of antifungal drugs that stimulate PCD.
11. PCD related signalling pathways in pathogenic fungi

Biella et al. [117] reported that the response of the chestnut blight fungus *Cryphonectria parasitica* to infection with a viral dsRNA hypovirulence factor resembled PCD. Using microarrays to look for genes that were differentially regulated following infection with the virus, 295 sequences (out of 2,200) were found with changed abundance [118]. Using differential display, Chen et al. [119] observed that 65% of the global changes initiated by viral infection could be reproduced by manipulating G-protein and cAMP signalling pathways – indirectly supporting a link between death responses and Ras-cAMP-PKA activity in fungi.

Direct evidence of Ras-cAMP-PKA involvement in fungal cell death responses comes from studies of a number of pathogens including *Colletotrichum trifolii* (a pathogen of alfalfa) and *C. albicans*. In *C. trifolii*, expression of a hyperactive oncogenic fungal Ras protein (DRas) elevates the production of ROS leading to abnormal fungal growth and apoptosis-like cell death when grown under nutrient deprived conditions [120]. Addition of antioxidants such as N-cysteine, diphenylene iodonium, or proline can however rescue cells from undergoing apoptosis. Proline was found to have a general suppressive effect as a ROS scavenger, perhaps mediated by an increased level of catalase activity in addition to a well-characterized role as an osmolyte.

In *C. albicans*, mutations that block Ras-cAMP-PKA signalling (*ras1Δ, cdc35Δ, tpk1Δ, tpk2Δ*) suppress or delay the apoptotic response induced by weak acid exposure [121]. In contrast mutations that stimulate signalling (*RAS1*val13 or pde2Δ) accelerate the rate of entry of cells into apoptosis when cells are treated with low doses of weak acid. Pharmacological stimulation of the Ras-cAMP-PKA pathway (either with dibutyryl cAMP, caffeine, or forskolin) enhances killing, whilst inhibition of Ras with lovastatin reduces apoptotic cell death. Transient increases in endogenous cAMP occur under conditions that stimulate apoptosis, but not stress or growth arrest indicating that there may be a separation of the activity of the Ras-cAMP-PKA pathway under stress and death inducing conditions.

Studies of the response of *S. cerevisiae* cells treated with the plant defence molecule osmotin, shed more light on this idea, since the production of ROS, expression of antioxidant proteins and the apoptotic response are partially dependent upon an induced suppression of the *RAS2/cAMP* pathway [104]. *RAS2*G19V, a dominant active allele of Sc *RAS2*, increases sensitivity of cells to osmotin and a null mutant shows reduced sensitivity. The response can be linked specifically to the Ras-PKA rather than the Ras-MAPK signalling pathway because the effects of the dominant active allele are also seen in a ste20 background. Consistent with osmotin induced Ras-PKA signalling, a *bcy1* null, with constitutively active PKA activity, exhibits significantly increased sensitivity to osmotin. De-repression of STRE-dependent transcriptional responses in *ras2* mutants [122] might account for the elevated resistance of *RAS2* nulls to stress treatments - a view further supported by the finding that during osmotin induced PCD, both STRE-element and YRE-reporter constructs are repressed [104]. It might therefore be argued that the balance between stress and apoptotic signals determines cell fate, and that osmotin stimulates pro-apoptotic ROS
production via the activation of the RAS2/cAMP pathway which in turn inhibits YRE (Yap1-dependent) and STRE-mediated antioxidant stress response.

Over-expression of plant defence molecules induces a hyper-branching phenotype or the formation of spiral hyphae [104] and growth inhibition per se has long been linked to altered patterns of hyphal branching [123, 124]. Ras-signals have been linked to morphogenesis in a number of fungi (see [125] for a review), however a study of the link between death and morphogenesis in C. albicans showed that it could not be attributed to any of the known signalling pathways (EFG1, RIM101, TEC1, CPH1) that contribute to morphogenesis [36]. Morphogenesis could however require the integration of many signals and pathways, including Ras under the specific conditions examined.

G-protein signals have been linked to apoptosis of Aspergillus nidulans induced by osmotin and the antifungal protein PAF, a small basic cysteine rich antifungal protein produced by Penicillium chrysogenum [105]. PAF-treatment induces hyperolarization of the cell membrane which is accompanied by PS exposure, ROS production and a TUNEL positive phenotype. A dominant-interfering mutant of fadA, which leads to constitutive inactivation of heterotrimeric G-protein signals [126] confers resistance to both osmotin [127] and PAF [105].

Few studies of pathogenic fungi have looked at signalling pathways other than Ras. However, several lines of evidence suggest that Ca\(^{2+}\)/calmodulin/calcineurin signals might affect the fungal death response. In S.cerevisiae apoptosis induced by pheromone treatment and salt stress have been shown to be influenced by mutations in calmodulin / calcineurin signalling pathway [128,129]. In addition, azole activity against S. cerevisiae is reduced by the addition of Ca\(^{2+}\) and enhanced by the addition of EGTA [130]. Inhibitors of the Ca\(^{2+}\) binding regulatory protein calmodulin such as fluphenazine, calmidazolin and W-7, as well as inhibitors of Ca\(^{2+}\)-dependant calmodulin-regulated phosphatase, calcineurin (cyclosporin and FK506) enhance azole activity. Consistent with these findings mutations that constitutively activate calcineurin demonstrate reduced azole susceptibility. When CRZ1 (a transcription factor regulated by calcineurin) is disrupted cells also show enhanced azole sensitivity - clearly indicating that the cell integrity pathway is important for the action of these drugs.

Sanglard et al. [131] reported that FK506 treatment of fluconazole treated C. albicans cells induced a fungicidal, rather than a fungistatic response, which could have very important ramifications for future drug therapy regimens. Deletion of CYP1 prevented the fungicidal activity, implying that a cyclophilin was essential for fluconazole toxicity. A similar effect of FK506 has recently been reported in Aspergillus fumigatus when cells are treated with caspofungin or nikkomycin Z [132].

Using nested, iterative PSI-BLAST searches, Uren et al. [133] identified a family of caspases, metacaspases and paracaspases in plants, animals and fungi. In fungi several metacaspases have been found; whilst S. cerevisiae, C. albicans, S. pombe and have single metacaspase encoding genes (YCA1/MCA1 and PCA1 respectively), A. fumigatus, A. nidulans and N. crassa appear to have two each [99,112,134,135]. Many studies have now shown that apoptosis in yeast may be dependent upon the
activity of the metacaspases [39, 136-138]. In some scenarios however the apoptotic killing response does appear to be metacaspase independent [40,41,139,140].

To date experimental studies of the role of metacaspases in the cell death response of pathogenic fungi have been limited to Aspergillus fumigatus [43,44]. Stationary phase cultures of A. fumigatus exhibit strong intracellular activity against substrates specific for caspase-1 and -8 and the development of an apoptotic phenotype is blocked by Z-FAD-fmk. However deletion of both casA and casB, the two genes encoding the mtacaspases, had little effect on measurable caspase activity, viability of hyphae or pathogenicity [44]. PS-exposure in the double knock-out strain was strongly abrogated, leading Richie et al [44] to explore other possible functions for the casA and casB genes, including a role in endoplasmic reticulum homeostasis.

Other "non-classical" cell death pathways may be linked to the death of fungal cells and tissues. The development of turgor pressure in appressoria in the rice-blast fungus Magnaporthe grisea is a prerequisite for pathogenicity [141,142] and recently this process has been shown to be reliant upon the autophagic death of the germinating spore [45]. Moreover, knock-out mutants of MgATG8 arrest conidial death, and prevent pathogenicity, showing that the blocking of a fungal cell death response, rather than its stimulation, can also lead to control. Blocking of fungal PCD might also be useful is the control of many other fungi, including the economically important rust fungi. Whilst there have been no overt studies of PCD in rusts, it is evident that in some situations the death of support cells in rusts is essential for the dispersal of others [143]. Specifically terminal aeciospores are normally separated by dead suspensor cells. Clearly prevention of this step (blocking death) could prevent dissemination of this important group of pathogens.

12. Genetic screens for potential antifungal drug targets

In an ongoing exploration, some 30 fungal genomes have been fully sequenced, which currently includes 18 hemiascomycetes, 8 euascomycetes and 4 basidiomycetes [144]. In total, 17 of these sequenced genomes are from fungal pathogens, with the long term prospect that many more will be sequenced in the future. This enormous bioinformatic resource is now being explored by the pharmaceutical and agrochemical industries in the search for genes, conserved between species, that might be useful targets for future antifungal drug therapies. Potential drug targets are typically prioritized in terms of their degree of essentiality, broad-spectrum potential, drug target potential, fungal specificity, availability of functional assays, and amenability to high-throughput screening [145].

Recognizing the need for broad-spectrum antifungals, Liu et al [145] identified 240 putative antifungal targets that were conserved among 10 fungal species in order to develop a system to identify target-specific inhibitors. Essentiality for a selection of the genes was then determined in C. albicans using a repressible CaMET3 promoter. The value of this approach is that not only is the target known a priori, which helps with the subsequent phase I development of the drug or fungicide, the impact of down-regulating the gene can be directly assessed. The use of dominant selectable markers (eg NAT1 conferring resistance to nourseothricin) and in vivo regulatable doxycycline-sensitive promoters (eg the GRACE™ strain collection of C. albicans,[146]) is particularly attractive for the validation of the essentiality of targets prior to drug
screening. Such bioinformatic screens have yet to produce clinically useful drugs, though the potential is clearly there [147].

Expression of pro-apoptotic members of the BCL-2 family of proteins, Bax and Bak, have been shown to kill yeast cells, and cell death is typically associated with an apoptotic phenotype [148-150]. Expression of a codon-optimized BAX gene in *Candida albicans* has been found to result in growth inhibition and cell death. By fusing Bax with GFP, the cell death-inducing effect of Bax was increased due to reduced proteolytic degradation of the Bax protein [151]. However, not all fungi respond in the same way to heterologous pro-apoptotic proteins, with expression of Bax in *Pichia pastoris* leading to growth arrest accompanied by the condensation of chromatin, and the accumulation of autophagic bodies [152], but no other apoptotic features.

In the search for novel antifungal drug targets we shouldn't just restrict our search to essential genes, or to studying the effects of the expression of heterologous pro-apoptotic proteins since the over-expression of many endogenous genes can also lead to growth arrest / cell death. Such genes are involved with many different biological processes but notably include components of the cytoskeleton [153-156] and a variety of signal transduction pathways [157-161]. In genome wide library screens using cDNA or genomic clones, lethal effects have been observed for *ABP1, ACT1, ARF2, ATE1, AU1, BIK1, BNI1, BOI1, ERG6, GCL17, HSF1, KARI, MCM1, NHP6A, NHP6B, NPS1, NSRI, NTH1, PRK1, PSP1, RBP1, RHO1, STE4, STE11, STE12, SAC7, SEC17, SIR1, SNU114, SRP40, TPK1, TPK3, TUB1* and *URA2* [162-165]. Whilst the induction of PCD has not been explicitly studies in these investigations, it is intriguing to note that both *BNI1* (Gin2) and *BOI1* (Gin7) produce cells with multiple DAPI staining bodies - perhaps hinting at evidence of nuclear fragmentation and apoptosis [165]. Often death in an over-expression screen will not due to the increased activity of a dedicated pro-death protein, but due to an imbalance in some unrelated critical process, nevertheless, such screens could provide a useful starting point to look for pro-death functions.

The majority of studies of essential genes, or genes that when over-expression prevent growth, have not so far discriminated between the responses that are lethal and those that merely cause growth arrest. It may therefore be of considerable value to ascertain the degree to which shutting off/inducing gene expression induces killing, and of course by what route. Performing screens under conditions that stimulate PCD may also allow antagonists of PCD to be identified that have anti/pro-apoptotic properties. Indeed, we can speculate that many of the ‘essential’ genes that have been described in fungi may have such anti-apoptotic roles.

A final area that could be explored further in the search for novel antifungals that stimulate fungal PCD relates to the response of a fungal pathogen to its host during infection, in particular the events that accompany its clearance by the host immune system (plant or animal). *C. albicans* infections are controlled in immuno-competent individuals through the activity of both the innate and adaptive immune system; indeed defects in the innate immune system are often responsible for predisposing patients to disseminated disease. Macrophages and neutrophils provide some of the primary lines of defence,
consequently their interaction with *C. albicans* cells has been the subject of a large number of studies (see review in [166]). It is apparent that the interaction results in a major re-organization or re-programming of the transcriptional activity of both the host [167-169] and fungal cells [170, 171]. Recently Fernandez-Arenas et al. [172] produced a model, based upon combined proteome and transcriptome data obtained from *C. albicans* cells ingested by RAW264.7 macrophages, indicating that the changes observed in the actin cytoskeleton and mitochondrial functioning could be associated with the onset of two distinct pathways of killing: autophagic death or apoptosis. Clearly, further work needs to be undertaken to unravel the nature of the killing mediated by immune cells, but the information obtained could prove to be very useful in designing therapies that manipulate the delicate balance between a pathogen and its host.

**Conclusion**

This review has examined what little we do know about the cell biology of death responses in pathogenic fungi and shows how a combination of cell biological approaches, functional genetic analyses, genetic screens and global profiling technologies may just begin to unravel this important, but neglected, aspect of fungal growth and development. Furthermore, the existence of a number of discrete endogenous cell suicide pathways in fungi might be usefully exploited in the search for and design of novel therapies in the future.

**Acknowledgements**

The author wishes to apologize to any researchers whose relevant work was not cited or discussed in this review. Funding for this work was supported by grant funding from the BBSRC (BB/C501176/1).

**References**


glycosyl and calcineurin/Crz1 functions as a signal initiator of the high osmolarity glycerol 3553.


Calcineurin inhibition or mutation e 959. involvement in antifungal tolerance, c 12 Saccharomyces cerevisiae 12 plants,


Comparative analysis of programmed cell death pathways in filamentous fungi, BMC Genomics. 6 (2005) 177.


